Method for reducing scarring during wound healing using antisense compounds directed to CTGF
AssigneesExcaliard Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., Northwestern University
InventorsThomas A. Mustoe, Nicholas M. Dean, Mark Sisco, Zol Kryger, C. Frank Bennett
Life of this patent
Estimating the term…
Abstract
This invention provides a method for reducing hypertropic scarring resulting from dermal wound healing in a subject in need which comprises administering to the subject an antisense oligonucleotide which inhibits expression of connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring.
Claims16
A method for reducing hypertrophic scarring resulting from dermal wound healing in a subject in need thereof which comprises administering directly to the subject's wound an antisense compound which targets a nucleic acid encoding, and inhibits expression of, connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring, wherein the antisense compound comprises an antisense oligonucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, wherein the antisense compound is to be administered intermittently with each subsequent administration being effected at least 4 days after the prior administration and wherein the antisense compound is administered in an amount effective to reduce scarring without having an adverse effect on wound healing.
A method for reducing hypertrophic scarring resulting from dermal wound healing in a subject in need thereof which comprises administering directly to the subject's wound an antisense compound which targets a nucleic acid encoding, and inhibits expression of, connective tissue growth factor (CTGF) in an amount effective to inhibit expression of CTGF and thereby reduce hypertrophic scarring, wherein the antisense compound comprises an antisense oligonucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:1 and SEQ ID NO:2, wherein the antisense compound is to be administered in an amount effective to reduce scarring without having an adverse effect on wound healing.
Dependencies are inferred from the claim text.